Close
Smartlab Europe
Inizio Ignite

Chugai and NTT DATA Complete Demonstration of AI-based Clinical Trial Efficiency Solution

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Digital Tools Accelerating Drug Delivery Development

Exploration of how computational modeling, high-throughput screening, and digital twins are revolutionizing the pharmaceutical R&D process to optimize formulation efficiency.

GSK Targets Faster Drug Development, Selective Acquisitions

GSK’s new chief executive, Luke Miels, said the drugmaker...

UK and Japan Strengthen Science and Technology Ties by £33bn

The UK and Japanese governments have announced a wide-ranging...
- Advertisement -

Chugai Pharmaceutical Co., Ltd. and NTT DATA Corporation have conducted a demonstration test of a solution for improving the efficiency of clinical trial-related document preparation using AI technology from January to June, 2020.

Clinical trial operations require the creation of a variety of documents and procedures from planning to implementation and application for drug approval. NTT DATA has been developing a solution based on the concept of improving the process efficiency of documentation, for example, by automatically creating clinical trial-related documents from a clinical trial protocol1). In this demonstration, Chugai and NTT DATA are collaborating by conducting concept verification, evaluating the usefulness of this solution and identifying future system issues.

Based on the results of this demonstration, NTT DATA aims to provide commercial services of this solution in FY2021. Furthermore, based on the cooperative relationship between the two companies obtained through this demonstration, we will collaborate and accelerate our efforts toward digital transformation of clinical development operations

New drug development is a process that involves research, collection and analysis of clinical data in clinical trials, and evaluation of efficacy and safety. It usually takes about 9 to 17 years on average to launch a new drug2). Both pharmaceutical companies and medical institutions participating in clinical studies have expended so much effort to ensure the quality of clinical trial activities and data. In addition, efficient development of high-quality clinical trial-related documents is a common challenge among pharmaceutical companies.

NTT DATA is developing a cross-pharmaceutical company/clinical site total solution platform for clinical trials to connect a wide range of clinical trial processes through the most advanced IT technology to help accelerate new drug development.

Under the goal of optimization of all value chains, one of the basic strategies of CHUGAI DIGITAL VISION 20303), Chugai aims at further acceleration of clinical trial processes. Chugai supports NTT DATA’s initiative and conducted the demonstration test jointly with NTT DATA to develop a new solution using AI technology, leveraging Chugai’s extensive experience.

The solution, as one of total solution platforms for clinical trials, allow sequential and comprehensive generation of various clinical trial-related documents (such as informed consent form for patients, statistical analysis plan, case report form to enter patients’ clinical trial data, and clinical study report summarizing the clinical trial results), using data from the protocol as input information, through AI technology, as well as technology components such as ontology4) and semantics5).

Latest stories

Related stories

Digital Tools Accelerating Drug Delivery Development

Exploration of how computational modeling, high-throughput screening, and digital twins are revolutionizing the pharmaceutical R&D process to optimize formulation efficiency.

GSK Targets Faster Drug Development, Selective Acquisitions

GSK’s new chief executive, Luke Miels, said the drugmaker...

UK and Japan Strengthen Science and Technology Ties by £33bn

The UK and Japanese governments have announced a wide-ranging...

Artificial Intelligence in Drug Formulation Development

Investigation into the role of machine learning and predictive modeling in streamlining the optimization of pharmaceutical recipes and reducing the time-to-market for new therapies.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »